Our laboratory is focused on surveillance and early detection of cancer by utilizing circulating RNA analytes as minimally invasive biomarkers.

We have established circulating RNA as a robust biomarker analyte by optimizing processes of purifying circulating extracellular vesicles and total RNA from small volumes of human plasma.  By characterizing novel RNA biomarkers comprised of SNP, INDEL and fusion variants it has enabled us to develop lab based tests facilitating identification of early-stage cancer patients. Circulating mutation profiles provide insights about aberrant pathways in individual patients and highlight actionable mutations useful in targeted therapeutics.

The laboratory is focused on understanding cancer progression in terms of metabolism associated changes in tumors which can be linearly detected before and after therapy in a non-invasive manner.